Vaccines-2013 - OMICS Group

Recommendations

Info

Pirouz Daftarian, J Vaccines Vaccin 2013, 4:5http://dx.doi.org/10.4172/2157-7560.S1.0163 rd International Conference onVaccines & VaccinationJuly 29-31, 2013 Embassy Suites Las Vegas, NV, USAYour vaccine is served; BON APPETIT: An oral DNA carrying nanovaccine targets APCand eradicates melanoma in micePirouz DaftarianUniversity of Miami, USACurrently, one the most promising vaccine strategy that shows promise in treating cancers consists of personalized dendriticcells (DCs) loaded with antigens. The universal benefits of such cell based vaccines are limited as they are costly and requirespecialized techniques. Here, we present the use of a nanocarrier that carries antigens and targets predominantly DCs, in vivo, hasintrinsic immunopotentiating effects, and works orally. The platform, peptide-derivatized-dendrimer (PDD) where the coupledpeptide is an MHC class II ligand to home onto professional antigen presenting cells (APC). PDD has a positive net charge andtherefore forms a complex with antigens (protein or DNA plasmids). Furthermore, since a universal T helper epitope is tailoredas APC recognition peptide, PDD significantly enhances immune responses. The built-in universal T epitope has two roles inPDD, i) targets the flank of MHC class II of and ii) activate the immune system of >95% of the human population, negatingMHC restriction. Analysis of peritoneal cells and of the draining lymph nodes upon injection of PDD/GFP-DNA complex inmice resulted in GFP expression in >80 of APC. Injection of PDD/TRP2 DNA (plasmids harboring TRP2 complexed with PDD)resulted in the rejection of established B16 melanoma tumors. Next, the oral enteric coated PDD formulation was optimized andone administration of oral formulation of PDD/OVA-DNA could reject OVA/B16 melanoma tumors in 100% of vaccinated mice.Interestingly, oral PDD elicited strong T cell and humoral responses upon a single oral gavage.pdaftarian@med.miami.eduJ Vaccines Vaccin 2013ISSN: 2157-7560, JVV an open access journalVaccines-2013July 29-31, 2013Volume 4 Issue 5Page 72
Young Research ForumSession ChairPeter L NaraBiological Mimetics, Inc., USADay 2 July 30, 2013Session IntroductionTitle: Promising horizons: Physicians as HPV vaccine advocatesSana Shahram, University of British Columbia, CanadaTitle: Production and characterization of monoclonal antibodies to Ebola glycoproteinsHumberto Hernandez, University of Texas Medical Branch, USATitle: Peptide/IFA emulsions limit tumor-specific CD8+ T cells tumor traffickingYared Hailemichael, The UT MD Anderson Cancer Center, USATitle: Tetravalent protein vaccine against Staphylococcus aureusNisha Nair, Amrita Centre for Nanosciences and Molecular Medicine, IndiaTitle: 2009 H1N1 pandemic influenza virus-like particle vaccine efficacyFu Shi Quan, Kyung Hee University School of Medicine, KoreaTitle: RNAi-based characterisation of tegument annexin as a novel vaccine candidate againstschistosomiasisYee Leow, Queensland Institute of Medical Research, AustraliaTitle: DNA vaccine encoding Hantavirus Gn, targeted to the MHC class II compartment by LAMP,significantly elicits specific immune responses and induces immune protection againstHantavirus challenge in vivoDongbo Jiang, The Fourth Military Medical University, P.R.ChinaTitle: Safety and immunogenicity of an inactivated whole-virion chromatographic vaccine withaluminum against influenza A (H1N1) pdm09: A randomized, blinded, dose-dependentplacebo-controlled clinical studyKaissar Tabynov, Research Institute for Biological Safety Problems, KazakhstanTitle: Effectiveness of BCG vaccination in preventing tuberculosisAhtisham Ul Haq, Service Institue of Medical Sciences, PakistanTitle: Immunomodulatory functions of defensins, innate molecules, as mucosal adjuvant with thepeptide antigens of HIV-1 at the mucosal surfacesTeena Mohan, All India Institute of Medical Sciences, IndiaPage 73
Page 1 and 2:
111 th OMICS Group ConferenceJuly 2
Page 3 and 4:
Medical SciencesISSNAddiction Resea
Page 5 and 6:
Impact Factors (IF) and Index Coper
Page 7 and 8:
111 th OMICS Group Conference3 rd I
Page 9 and 10:
Journal of Clinical & Cellular Immu
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Clinical Microbiology-2013OMICS Gro
Page 17 and 18:
Immunology Summit-2013OMICS Group i
Page 19 and 20:
Probiotics-2013OMICS Group is organ
Page 21 and 22: Virology-2013OMICS Group is organiz
Page 23 and 24: 111 th OMICS Group Conference3 rd I
Page 25 and 26: Because of heightened awareness of
Page 33 and 34: Ara Hovanessian, J Vaccines Vaccin
Page 35 and 36: Nikolai Petrovsky, J Vaccines Vacci
Page 39 and 40: Robert E. Sievers et al., J Vaccine
Page 41 and 42: Xiao-Qing Wei, J Vaccines Vaccin 20
Page 43 and 44: Campbell Bunce, J Vaccines Vaccin 2
Page 45 and 46: Hong Xin, J Vaccines Vaccin 2013, 4
Page 47 and 48: Diane Longo et al., J Vaccines Vacc
Page 49 and 50: Track 33: Novel Approaches in Desig
Page 51 and 52: Takashi Kei Kishimoto, J Vaccines V
Page 53 and 54: Benjamin Petsch, J Vaccines Vaccin
Page 55 and 56: A. Bennett Jenson et al., J Vaccine
Page 57 and 58: Milan Raska et al., J Vaccines Vacc
Page 59 and 60: Muhammad Ali A. Shah et al., J Vacc
Page 61 and 62: Track 44: Vaccines against Infectio
Page 63 and 64: Haval Shirwan, J Vaccines Vaccin 20
Page 65 and 66: Rainer Fischer, J Vaccines Vaccin 2
Page 67 and 68: Alwyn Rapose, J Vaccines Vaccin 201
Page 69 and 70: Saroj Basak, J Vaccines Vaccin 2013
Page 71: Gisela Gonzalez, J Vaccines Vaccin
Page 75 and 76: Humberto Hernandez et al., J Vaccin
Page 77 and 78: Nisha Nair et al., J Vaccines Vacci
Page 79 and 80: Leow Yee et al., J Vaccines Vaccin
Page 81 and 82: Kaissar Tabynov et al., J Vaccines
Page 83 and 84: Teena Mohan et al., J Vaccines Vacc
Page 85 and 86: Track 5 & 95: Manufacturing, Produc
Page 87 and 88: Graham Clarke, J Vaccines Vaccin 20
Page 89 and 90: Obradovic Zarema et al., J Vaccines
Page 91 and 92: Abdur Razzaque Sarker et al., J Vac
Page 93 and 94: Omer Qutaiba B. Al-lela et al., J V
Page 97 and 98: Regina Heidenreich et al., J Vaccin
Page 99 and 100: Leow Y et al., J Vaccines Vaccin 20
Page 101 and 102: Zafer Kurugol et al., J Vaccines Va
Page 103 and 104: Ates Kara et al., J Vaccines Vaccin
Page 105 and 106: Yurong Tan et al., J Vaccines Vacci
Page 107 and 108: Deryabin P.N. et al., J Vaccines Va
Page 109 and 110: Xiao-Yong Fan et al., J Vaccines Va
Page 111 and 112: Byung Chul Kim et al., J Vaccines V
Page 113 and 114: STS. Chitradevi et al., J Vaccines
Page 115 and 116: Yan Liang et al., J Vaccines Vaccin
Page 119 and 120: Afshineh Latifynia et al., J Vaccin
Page 121 and 122: Hemanta Koley et al., J Vaccines Va
Page 123 and 124:
Aleksandar Masic et al., J Vaccines
Page 125 and 126:
Hassen Mamo, J Vaccines Vaccin 2013
Page 127 and 128:
Oladipo Aina et al., J Vaccines Vac
Page 129 and 130:
Aiswariya Chidambaram, J Vaccines V
Page 131 and 132:
Birhanu Hurisa et al., J Vaccines V
Page 133 and 134:
Ghaffarifar F et al., J Vaccines Va
Page 135 and 136:
Mathan Periasamy et al., J Vaccines
Page 137 and 138:
Rania Abdel Hay, J Vaccines Vaccin
Page 139 and 140:
Samuel Teshome, J Vaccines Vaccin 2
Page 141 and 142:
Page 143 and 144:
Birhanu Hurisa et al., J Vaccines V
Page 145 and 146:
Dhrubajyoti Nag, J Vaccines Vaccin
Page 147 and 148:
Belachew Etana et al., J Vaccines V
Page 149 and 150:
Fatemeh Ghaffarifar et al., J Vacci
Page 151 and 152:
Moustafa A.F. Abbas et al., J Vacci
Page 153 and 154:
Prerna Chaudhary, J Vaccines Vaccin
Page 155 and 156:
Sandeepkumar R. Chauhan et al., J V
Page 157 and 158:
Veronica Rainone et al., J Vaccines
Page 159 and 160:
Page 159
Page 161 and 162:
Previous111 th OMICS Group Conferen
Page 163 and 164:
PreviousWorld Congress and Expo onB
show all

Vaccines-2013 - OMICS Group

Create successful ePaper yourself

Delete template?

Save as template?